#1 Clinical Trials Search in Europe

ABBV-8736

Clinical trials are studying ABBV-8736 in adults with moderate to severe Crohn’s disease. These studies aim to check safety, efficacy, and how the treatment affects the disease. The trial data here describe a Phase 2 study in a large adult population.

Table of Contents

Trial overview

This is an interventional study, which means researchers give study treatment and then measure the results in participants.[1] The trial is authorised and is studying adults with moderate to severe Crohn’s disease.[1]

The study title says it is looking at targeted therapies for treatment of this condition, and the brief summary says the goal is to evaluate safety, efficacy, and the mechanistic profile of the studied therapies.[1] ABBV-8736 is one of the listed study drugs in this trial.[1]

Who can participate

The source data show that the target population is adult participants with moderate to severe Crohn’s disease.[1] No other eligibility details are provided in the trial information given here.[1]

What the study measures

The main endpoint is endoscopic remission at Week 12.[1] Endoscopic remission means that a scope exam of the bowel shows little or no active disease.[1]

The study also aims to assess safety and efficacy.[1] Safety means watching for problems during the study, while efficacy means how well the treatment works for the disease.[1]

Trial phase and size

This study is in Phase 2.[1] Phase 2 trials usually focus on whether a treatment may work and continue to collect safety information.[1]

The planned enrollment is 1,072 participants.[1] Enrollment means the number of people the study hopes to include.[1]

Study treatments

ABBV-8736 is listed among several targeted therapies in the study.[1] The other listed treatments are ABBV-066, Lutikizumab, ABBV-382, and ABBV-066 with Risankizumab.[1]

The source data list different ways these study drugs are given, including intravenous use, subcutaneous injection, and intramuscular use.[1] These are ways medicine can be given into a vein, under the skin, or into a muscle.[1]

Why this trial matters

People with moderate to severe Crohn’s disease often need treatments that reduce bowel inflammation and improve disease control.[1] This study is designed to help researchers learn whether ABBV-8736 and the other targeted therapies can help with that goal.[1]

Because the study measures endoscopic remission, it looks not only at symptoms but also at what is seen directly inside the bowel.[1] That can give a clearer picture of whether the disease is truly improving.[1]

Trial IDPhaseCondition studiedStatusEnrollmentMain endpoint
2024-513009-30-00Phase 2Moderate to Severe Crohn’s DiseaseAuthorised1072Endoscopic remission at Week 12

FAQ

  • What is being studied with ABBV-8736? The trial is studying ABBV-8736 as one of several targeted therapies for adults with moderate to severe Crohn’s disease. The main goal is to see how well it works and how safe it is.
  • Who can take part in the trial? The study is for adult participants with moderate to severe Crohn’s disease. The source data do not list more detailed entry rules.
  • What phase is the ABBV-8736 trial? This is a Phase 2 trial. Phase 2 studies usually look more closely at whether a treatment works and continue to monitor safety.
  • What is the main result the study is measuring? The main endpoint is endoscopic remission at Week 12. Endoscopic remission means the doctor sees little or no active disease during a scope exam of the bowel.
  • How many people are planned for this study? The planned enrollment is 1,072 participants. This means the study aims to include that many people.

Ongoing Clinical Trials on ABBV-8736

  • Study of Lutikizumab, ABBV-382, and Risankizumab for Adults with Moderate to Severe Crohn’s Disease

    Recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Bulgaria Croatia Czechia Denmark +17

Glossary

  • Crohn’s disease: A long-term disease that causes swelling and damage in the digestive tract. It can lead to belly pain, diarrhea, and other symptoms.
  • Moderate to severe: A level of illness that is more serious than mild disease and may cause stronger symptoms or more bowel inflammation.
  • Adult participants: People in the study who are 18 years old or older.
  • Clinical trial: A research study in people that tests whether a treatment is safe, works, and should be studied further.
  • Interventional study: A study where researchers give a treatment to participants and then measure the results.
  • Phase 2: A trial stage that looks more closely at how well a treatment works and continues checking safety.
  • Targeted therapy: A treatment designed to act on specific parts of a disease process.
  • Endoscopic remission: A state where a scope test shows very little or no visible active disease inside the bowel.
  • Week 12: The point 12 weeks after the start of treatment when the study checks a result.
  • Enrollment: The number of people the study plans to include.

References